High risk profile(s)-BRCA1 or BRCA2 Posts on Medivizor
Navigation Menu

High risk profile(s)-BRCA1 or BRCA2 Posts on Medivizor

Evaluating olaparib for metastatic breast cancer with BRCA1/2 and other gene mutations.

Evaluating olaparib for metastatic breast cancer with BRCA1/2 and other gene mutations.

Posted by on Dec 13, 2020 in Breast cancer | 0 comments

In a nutshell This study was carried out to examine the effectiveness of olaparib (Lynparza) for the treatment of metastatic breast cancer (MBC; cancer that has spread) with gene mutations (abnormalities). The authors found that this treatment was effective for patients with MBC with BRCA1/2 mutations. Some background Breast cancer (BC) is one of the...

Read More

Olaparib for treating breast cancer that has spread

Olaparib for treating breast cancer that has spread

Posted by on Mar 5, 2019 in Breast cancer | 0 comments

In a nutshell This study determined whether treating breast cancer that has spread (metastatic) with olaparib (Lynparza) resulted in better outcomes and fewer side effects compared to chemotherapy. The study found that treatment with olaparib led to similar survival outcomes compared to chemotherapy.  Some background There are...

Read More

Does pregnancy affect survival?

Does pregnancy affect survival?

Posted by on Nov 16, 2013 in Breast cancer | 0 comments

Does pregnancy affect survival? This study evaluated the effect of pregnancy on the survival of women with BRCA associated breast cancer. Hereditary breast cancer (associated with a mutation in either the BRCA1 or BRCA2 gene) typically presents itself in younger women. Consequently, the onset of breast cancer often overlaps with pregnancy....

Read More

Comparing the effectiveness of bilateral mastectomy and surveillance in BRCA1 and BRCA2 mutation carriers

Posted by on Sep 8, 2013 in Breast cancer | 0 comments

In a nutshell This study compared bilateral risk-reducing mastectomy and surveillance methods for reducing the risk of breast cancer in women with the BRCA1 or BRCA2 genetic mutations. Some background BRCA 1 and BRCA 2 are genetic mutations which increase the risk of breast cancer (BC). Women with these mutations can try to reduce their BC risk...

Read More

Tamoxifen reduces the risk of contralateral breast cancer in women with BRCA1 or BRCA2

Posted by on Aug 25, 2013 in Breast cancer | 0 comments

In a nutshell This study examined whether tamoxifen (nolvadex) can reduce the risk of contralateral breast cancer in women diagnosed with breast cancer and the BRCA1 or BRCA2 genetic mutation. Some background The BRCA1 and BRCA2 genetic mutations are associated with a high risk of developing breast cancer. While prophylactic mastectomies (a...

Read More

What is the preferred duration of chemotherapy? – A review of clinical trials

What is the preferred duration of chemotherapy? – A review of clinical trials

Posted by on Feb 24, 2013 in Breast cancer | 0 comments

The aim of this paper was to identify if a longer course of chemotherapy was better than a short course. The authors look at how long patients survived with metastatic breast cancer or with no further cancer progression. Breast cancer is called metastatic when it has spread from the breast to other parts of the body such as the lymph nodes, lungs,...

Read More

Does Tamoxifen reduce the risk of cancer in a second breast in BRCA1 and BRCA2 carriers?

Does Tamoxifen reduce the risk of cancer in a second breast in BRCA1 and BRCA2 carriers?

Posted by on Feb 24, 2013 in Breast cancer | 0 comments

In a nutshell The risk of breast cancer is high (~80%) in women who inherit a damaged (mutated) gene called BRCA1 or BRCA 2 (‘BRCA carriers’). Following the first diagnosis, their risk of developing another tumor in the second breast within 10 years is 30%. Some background Some types of breast cancer need estrogen (female sex...

Read More